HomeCompareADXS vs MRK

ADXS vs MRK: Dividend Comparison 2026

ADXS yields 331.37% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADXS wins by $2987.25M in total portfolio value
10 years
ADXS
ADXS
● Live price
331.37%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2987.30M
Annual income
$1,874,518,858.21
Full ADXS calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ADXS vs MRK

📍 ADXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADXSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADXS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADXS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADXS
Annual income on $10K today (after 15% tax)
$28,166.68/yr
After 10yr DRIP, annual income (after tax)
$1,593,341,029.48/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ADXS beats the other by $1,593,332,701.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADXS + MRK for your $10,000?

ADXS: 50%MRK: 50%
100% MRK50/50100% ADXS
Portfolio after 10yr
$1493.68M
Annual income
$937,264,328.18/yr
Blended yield
62.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ADXS
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-24.8
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADXS buys
0
MRK buys
0
No recent congressional trades found for ADXS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADXSMRK
Forward yield331.37%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$2987.30M$56.8K
Annual income after 10y$1,874,518,858.21$9,798.13
Total dividends collected$2879.16M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ADXS vs MRK ($10,000, DRIP)

YearADXS PortfolioADXS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$43,837$33,137.27$11,206$366.19+$32.6KADXS
2$182,667$135,761.45$12,650$502.35+$170.0KADXS
3$724,155$528,700.93$14,407$694.19+$709.7KADXS
4$2,733,677$1,958,830.81$16,585$967.82+$2.72MADXS
5$9,835,841$6,910,807.10$19,342$1,363.89+$9.82MADXS
6$33,762,918$23,238,567.70$22,913$1,947.19+$33.74MADXS
7$110,677,420$74,551,098.17$27,662$2,823.89+$110.65MADXS
8$346,821,277$228,396,437.05$34,159$4,173.35+$346.79MADXS
9$1,039,984,991$668,886,225.19$43,337$6,308.80+$1039.94MADXS
10$2,987,302,799$1,874,518,858.21$56,776$9,798.13+$2987.25MADXS

ADXS vs MRK: Complete Analysis 2026

ADXSStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Full ADXS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ADXS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADXS vs SCHDADXS vs JEPIADXS vs OADXS vs KOADXS vs MAINADXS vs JNJADXS vs ABBVADXS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.